Business Wire

Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research

Share

Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships with nine of the top centers in the region, including Charité – Universitätsmedizin Berlin, Centre Hospitalier Universitaire Vaudois (CHUV), Universitätsspital Basel, Technische Universität München (TUM), Uniklinikum Erlangen, Universitätsklinikum Leipzig, Inselspital Bern, Universitätsklinik Mannheim-Heidelberg and Medizinische Universität Wien. These collaborations signify unparalleled representation of patient populations, representing 24% of all outpatient cases and 15% of the total patients in the DACH region.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240703400559/en/

Guillaume Bézie, Director of Partnerships Western Europe: “The Western Europe network covering France, Benelux and DACH represents the largest pool of centres for Owkin. Partnering with top academic institutions is an inevitable asset for our expansion strategy, and we are delighted to showcase the ability to significantly increase our footprint in the DACH region. By capturing the diverse landscape of human health, we empower our AI to better address the unique needs of all individuals. With our partners, we are fully committed to accelerate the secondary use of multimodal patient data for the purpose of giving the right treatment for each patient.”

By analyzing vast datasets and identifying complex patterns across the nine hospitals, Owkin will use its AI engines and diagnostic tools to improve patient outcomes in Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), and Cardiovascular Disease (CVD). This will enable researchers to discover novel biomarkers, predict treatment responses, and develop more effective therapies tailored to individual patients.

  • BiomarkerPlus (Outcome prediction): Owkin will work with Inselspital Bern, Technische Universität München (TUM) and Universitätsspital Basel to analyze multimodal patient data to identify which early-stage prostate cancer patients are most likely to fail primary curative treatment and ultimately progress to more severe disease and anticipate if they may benefit from a different management strategy. Owkin is also partnering with Uniklinikum Erlangen (UKER) on MIBC to analyze H&E slides to detect FGFR3 mutations.
  • TargetMatch (Target discovery): In partnership with Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität and Medizinische Universität Wien, Owkin will access a high-quality multimodal dataset, including digitized histology and RNA-seq, to better understand the response to treatment for neoadjuvant chemotherapy and to identify new targets and treatment strategies in MIBC.
  • TrialPlus (Clinical trial optimization): Owkin’s partnership with Universitätsklinikum Leipzig aims to use machine learning techniques to enhance clinical trial design for CVD.
  • AI Diagnostics (MSIntuit® CRC): To further improve Owkin’s first CE-IVD-approved MSI pre-screening tool MSIntuit® CRC, Owkin will work in close collaboration with Uniklinikum Erlangen (UKER) to validate our upgraded MSIntuit CRC V2 on more diverse cohorts.

In addition to advancing research towards more personalized treatment strategies for patients with prostate cancer, MIBC and CVD, Owkin has also expanded its MOSAIC network, a global initiative to build the world’s largest spatial omics dataset in oncology with 7,000 patient samples across 7 cancer indications, bringing on Uniklinikum Erlangen, Charité – Universitätsmedizin Berlin and Centre Hospitalier Universitaire Vaudois (CHUV) to accelerate research across numerous therapeutic areas.

Dr. Philipp Mann, Principal Partnerships Manager Switzerland, Germany and Austria (DACH) said: “The healthcare system across the DACH region is an invaluable asset because it offers an extensive repository of reliable, comprehensive health data that can guide drug discovery and development strategies. The collaboration between Owkin and these institutions enhances the use of this data, driving innovation and fast-tracking medical advancements. With the combined expertise of these partners, the data can be transformed into actionable insights used to revolutionize patient care and improve health outcomes.”

About Owkin

Owkin is the first end-to-end AI-biotech unicorn on a mission to understand complex biology and derive new multimodal biomarkers through AI. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing federated technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240703400559/en/

Contacts

stephanie.libous@owkin.com

About Business Wire

Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

HiddenA line styled icon from Orion Icon Library.Eye